查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1229130

急性偏头痛药的全球市场:各药物类型 (麦角生物碱、止痛药、Triptans、其他)、给药途径、可用性、地区、国家的分析、市场规模、考察、竞争、COVID-19影响、预测 (2023～2028年)

Global Acute Migraine Drugs Market - Analysis By Drug Type (Ergot Alkaloids, Analgesics, Triptans, Others), Route of Administration, Availability, By Region, By Country: Market Size, Insights, Competition, Covid-19 Impact and Forecast (2023-2028)
出版日期: | 出版商: Azoth Analytics | 英文 260 Pages | 订单完成后即时交付

价格

全球急性偏头痛药的市场规模，从2021年的84亿美元，预计2023年～2028年以7.82％的年复合成长率成长。劳动人口的偏头痛盛行率上升和医疗保健支出增加，提高急性偏头痛药的需求。

Triptans，由于是选择性血清素受体促效剂，广泛用作偏头痛治疗药。由于提高脑内的血清素浓度，有控製发炎，收缩血管，结束头痛和偏头痛的效果。2021年的药物类型的占有率，Triptans系药物占整体约46％。

本报告提供全球急性偏头痛药的市场调查，市场及产品概要，市场成长的各种影响因素分析，市场规模的变化、预测，各种区分、各地区/主要国家的明细，竞争环境，市场占有率，主要企业简介等彙整资讯。

目录

第1章 市场背景

  • 范围、产品的展望
  • 摘要整理
  • 调查手法

第2章 策略性建议

第3章 全球急性偏头痛药市场:变化、预测

  • 宏观经济要素的影响分析
  • 生态系统分析
  • 仪表板
  • 市场规模、年复合成长率 (金额)
  • COVID-19影响
  • 市场分类:各药物类型
    • 市场概要
    • 市场规模、年复合成长率 (金额):麦角生物碱
    • 市场规模、年复合成长率 (金额):止痛药
    • 市场规模、年复合成长率 (金额):Triptans
    • 市场规模、年复合成长率 (金额):其他
  • 市场分类:各给药途径
    • 市场概要
    • 市场规模、年复合成长率 (金额):静脉内
    • 市场规模、年复合成长率 (金额):口服
    • 市场规模、年复合成长率 (金额):经鼻
    • 市场规模、年复合成长率 (金额):其他
  • 市场分类:各可用性
    • 市场概要
    • 市场规模、年复合成长率 (金额):店面销售
    • 市场规模、年复合成长率 (金额):处方

第4章 全球急性偏头痛药市场:地区分析

  • 调查对像地区
  • 地区的概述

第5章 南北美洲的急性偏头痛药市场:变化、预测

  • 概述
  • 市场规模、年复合成长率 (金额)
  • 主要的影响因素
  • 市场分类:各药物类型
  • 市场分类:各给药途径
  • 市场分类:各可用性
  • 市场分类:各国

第6章 欧洲的急性偏头痛药市场:变化、预测

  • 概述
  • 市场规模、年复合成长率 (金额)
  • 主要的影响因素
  • 市场分类:各药物类型
  • 市场分类:各给药途径
  • 市场分类:各可用性
  • 市场分类:各国

第7章 亚太地区的急性偏头痛药市场:变化、预测

  • 概述
  • 市场规模、年复合成长率 (金额)
  • 主要的影响因素
  • 市场分类:各药物类型
  • 市场分类:各给药途径
  • 市场分类:各可用性
  • 市场分类:各国

第8章 中东、非洲的急性偏头痛药市场:变化、预测

  • 概述
  • 市场规模、年复合成长率 (金额)
  • 主要的影响因素
  • 市场分类:各药物类型
  • 市场分类:各给药途径
  • 市场分类:各可用性
  • 市场分类:各国

第9章 市场动态

  • 市场动态的影响评估
  • 促进因素
  • 阻碍因素
  • 趋势

第10章 产业生态系统分析

  • 宏观经济要素的评估
  • 价值链分析
  • 波特的五力分析

第11章 竞争上的地位

  • 企业的产品定位
  • 市场地位矩阵
  • 市场占有率分析
  • 企业简介
    • Eli Lilly and Company
    • GSK plc.
    • Bayer AG
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd.
    • AbbVie Inc.
    • Novartis
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Boehringer Ingelheim

第12章 关于本公司、免责声明

Executive Summary

The global Acute Migraine Drugs market was worth USD 8.40 billion in 2021 and is anticipated to expand at a CAGR of 7.82% between 2023 and 2028. The rising prevalence of migraine among the working population, as well as increasing healthcare expenditure, are driving up demand for acute migraine medications.

Triptans are widely used migraine medications because they are selective serotonin receptor agonists. They work by increasing serotonin levels in the brain, which reduces inflammation and constricts blood vessels, thereby ending the headache or migraine. Triptans account for approximately 46% of the overall market share by drug type segment in 2021. For Mild pain treatment of Migraine, over-the-counter medications such as Naproxen, Ibuprofen, Aspirin, Acetaminophen, Pseudoephedrine, or phenylephrine are widely utilized.

With patients' suffering from migraine and the limitations of triptan, there are significant opportunities in the treatment of acute migraine. In this scenario, there are a number of novel therapeutic options that include Ubrelvy, Reyvow and Nurtec ODT. However, one of the treatments making huge inroads is Impel's Trudhesa, which is a self-administered drug device for the intranasal delivery of DHE. Trudhesa was approved by the FDA in September 2021.

Women account for about three-quarters of all migraine cases. Women aged 20 to 45 are the most prone to suffer from migraines. Moreover, hormonal variations in women may be a migraine trigger, and menstrual migraines affect around 60% of female migraineurs. The Americas accounted for a major share of the market in terms of value in 2021 and the region is expected to keep retaining the largest share of the overall sales of acute migraine drugs.

Scope of the Report

  • The report analyses the Acute Migraine Drugs Market by Value (USD Billion).
  • The report presents the analysis of the Acute Migraine Drugs market for the historical period of 2018-2021, the base year 2022 and the forecast period of 2023-2028.
  • The report analyses the Acute Migraine Drugs Market by Drug Type (Ergot Alkaloids, Analgesics, Triptans, Fragrance, Other Drug Types)
  • The report analyses the Acute Migraine Drugs Market By Route of Administration (Intravenous, Oral, Nasal, Other Routes of Administration)
  • The report analyses the Acute Migraine Drugs Market By Availability (Over the Counter, Prescription)
  • The Global Acute Migraine Drugs Market has been analysed by countries (United States, Canada, Germany, UK, France, Italy, Spain, China, Japan, India).
  • The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Drug Type and Availability
  • Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies profiled in the report include Eli Lilly and Company, GSK plc., Bayer AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Novartis, Merck & Co., Inc., Pfizer Inc., Boehringer Ingelheim.

Key Target Audience

  • Healthcare and Pharmaceutical Companies
  • Episodic migraine Patients
  • Leading Acute Migraine Drugs Brands
  • Research & Development Organizations

Table of Contents

1. Market Background

  • 1.1 Scope and Product Outlook
  • 1.2 Executive Summary
  • 1.3 Research Methodology

2. Strategic Recommendations

3. Global Acute Migraine Drugs Market: Historic and Forecast (2018-2028)

  • 3.1 Impact Analysis of Macro Economic Factors on Acute Migraine Drugs Market
  • 3.2 Global Acute Migraine Drugs Market: Ecosystem Analysis
    • 3.2.1 Migraine: Fact sheet
    • 3.2.2 Migraine - Nurtec ODT and Ubrelvy patient's Therapy abandonment data
    • 3.2.3 Pipeline scenario of Acute Migraine Drugs
    • 3.2.4 Annual Sales of Triptans and Non Triptans in the U.S
  • 3.3 Global Acute Migraine Drugs Market: Dashboard
  • 3.4 Global Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
  • 3.5 Impact of COVID-19 on Acute Migraine Drugs Market
  • 3.6 Global Acute Migraine Drugs Market Segmentation: By Drug Type (2018-2028)
    • 3.6.1 Global Acute Migraine Drugs Market, By Drug Type Overview
    • 3.6.2 Global Acute Migraine Drugs Market Size, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)
    • 3.6.3 Global Acute Migraine Drugs Market Size, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)
    • 3.6.4 Global Acute Migraine Drugs Market Size, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)
    • 3.6.5 Global Acute Migraine Drugs Market Size, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)
  • 3.7 Global Acute Migraine Drugs Market Segmentation: By Route of Administration
    • 3.7.1 Global Acute Migraine Drugs Market, By Route of Administration Overview
    • 3.7.2 Global Acute Migraine Drugs Market Size, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)
    • 3.7.3 Global Acute Migraine Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
    • 3.7.4 Global Acute Migraine Drugs Market Size, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)
    • 3.7.5 Global Acute Migraine Drugs Market Size, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)
  • 3.8 Global Acute Migraine Drugs Market Segmentation: By Availability
    • 3.8.1 Global Acute Migraine Drugs Market, By Availability Overview
    • 3.8.2 Global Acute Migraine Drugs Market Size, By Over The Counter, By Value, 2018H-2028F (USD Billion & CAGR)
    • 3.8.3 Global Acute Migraine Drugs Market Size, By Prescription, By Value, 2018H-2028F (USD Billion & CAGR)

4. Global Acute Migraine Drugs Market, Regional Analysis (2018-2028)

  • 4.1 Regional Coverage of the Study
  • 4.2 Regional Snapshot

5. Americas Acute Migraine Drugs Market: Historic and Forecast (2018-2028)

  • 5.1 Americas Acute Migraine Drugs Market: Snapshot
  • 5.2 Americas Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
  • 5.3 Americas Acute Migraine Drugs Market: Key Factors
  • 5.4 Americas Acute Migraine Drugs Market Segmentation: By Drug Type
    • 5.4.1 Americas Acute Migraine Drugs Market, By Drug Type Overview
    • 5.4.2 Americas Acute Migraine Drugs Market Size, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)
    • 5.4.3 Americas Acute Migraine Drugs Market Size, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)
    • 5.4.4 Americas Acute Migraine Drugs Market Size, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)
    • 5.4.5 Americas Acute Migraine Drugs Market Size, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)
  • 5.5 Americas Acute Migraine Drugs Market Segmentation: By Route of Administration
    • 5.5.1 Americas Acute Migraine Drugs Market, By Route of Administration Overview
    • 5.5.2 Americas Acute Migraine Drugs Market Size, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)
    • 5.5.3 Americas Acute Migraine Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
    • 5.5.4 Americas Acute Migraine Drugs Market Size, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)
    • 5.5.5 Americas Acute Migraine Drugs Market Size, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)
  • 5.6 Americas Acute Migraine Drugs Market Segmentation: By Availability
    • 5.6.1 Americas Acute Migraine Drugs Market, By Availability Overview
    • 5.6.2 Americas Acute Migraine Drugs Market Size, By By Over The Counter, By Value, 2018H-2028F (USD Billion & CAGR)
    • 5.6.3 Americas Acute Migraine Drugs Market Size, By Prescription, By Value, 2018H-2028F (USD Billion & CAGR)
  • 5.7 Americas Acute Migraine Drugs Market Segmentation: By Country
    • 5.7.1 Americas Acute Migraine Drugs Market Segmentation, By Country Overview
    • 5.7.2 United States Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
      • 5.7.2.1 United States Acute Migraine Drugs Market, By Drug Type
      • 5.7.2.2 United States Acute Migraine Drugs Market, By Route of Administration
      • 5.7.2.3 United States Acute Migraine Drugs Market, By Availability
    • 5.7.3 Canada Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
      • 5.7.3.1 Canada Acute Migraine Drugs Market, By Drug Type
      • 5.7.3.2 Canada Acute Migraine Drugs Market, By Route of Administration
      • 5.7.3.3 Canada Acute Migraine Drugs Market, By Availability
    • 5.7.4 Rest of Americas Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
      • 5.7.4.1 Rest of Americas Acute Migraine Drugs Market, By Drug Type
      • 5.7.4.2 Rest of Americas Acute Migraine Drugs Market, By Route of Administration
      • 5.7.4.3 Rest of Americas Acute Migraine Drugs Market, By Availability

6. Europe Acute Migraine Drugs Market: Historic and Forecast (2018-2028)

  • 6.1 Europe Acute Migraine Drugs Market: Snapshot
  • 6.2 Europe Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
  • 6.3 Europe Acute Migraine Drugs Market: Key Factors
  • 6.4 Europe Acute Migraine Drugs Market Segmentation: By Drug Type
    • 6.4.1 Europe Acute Migraine Drugs Market, By Drug Type Overview
    • 6.4.2 Europe Acute Migraine Drugs Market Size, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)
    • 6.4.3 Europe Acute Migraine Drugs Market Size, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)
    • 6.4.4 Europe Acute Migraine Drugs Market Size, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)
    • 6.4.5 Europe Acute Migraine Drugs Market Size, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)
  • 6.5 Europe Acute Migraine Drugs Market Segmentation: By Route of Administration
    • 6.5.1 Europe Acute Migraine Drugs Market, By Route of Administration Overview
    • 6.5.2 Europe Acute Migraine Drugs Market Size, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)
    • 6.5.3 Europe Acute Migraine Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
    • 6.5.4 Europe Acute Migraine Drugs Market Size, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)
    • 6.5.5 Europe Acute Migraine Drugs Market Size, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)
  • 6.6 Europe Acute Migraine Drugs Market Segmentation: By Availability
    • 6.6.1 Europe Acute Migraine Drugs Market, By Availability Overview
    • 6.6.2 Europe Acute Migraine Drugs Market Size, By By Over The Counter, By Value, 2018H-2028F (USD Billion & CAGR)
    • 6.6.3 Europe Acute Migraine Drugs Market Size, By Prescription, By Value, 2018H-2028F (USD Billion & CAGR)
  • 6.7 Europe Acute Migraine Drugs Market Segmentation: By Country
    • 6.7.1 Europe Acute Migraine Drugs Market Segmentation, By Country, Overview
    • 6.7.2 Germany Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
      • 6.7.2.1 Germany Acute Migraine Drugs Market, By Drug Type
      • 6.7.2.2 Germany Acute Migraine Drugs Market, By Route of Administration
      • 6.7.2.3 Germany Acute Migraine Drugs Market, By Availability
    • 6.7.3 United Kingdom Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
      • 6.7.3.1 United Kingdom Acute Migraine Drugs Market, By Drug Type
      • 6.7.3.2 United Kingdom Acute Migraine Drugs Market, By Route of Administration
      • 6.7.3.3 United Kingdom Acute Migraine Drugs Market, By Availability
    • 6.7.4 France Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
      • 6.7.4.1 France Acute Migraine Drugs Market, By Drug Type
      • 6.7.4.2 France Acute Migraine Drugs Market, By Route of Administration
      • 6.7.4.3 France Acute Migraine Drugs Market, By Availability
    • 6.7.5 Italy Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
      • 6.7.5.1 Italy Acute Migraine Drugs Market, By Drug Type
      • 6.7.5.2 Italy Acute Migraine Drugs Market, By Route of Administration
      • 6.7.5.3 Italy Acute Migraine Drugs Market, By Availability
    • 6.7.6 Spain Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
      • 6.7.6.1 Spain Acute Migraine Drugs Market, By Drug Type
      • 6.7.6.2 Spain Acute Migraine Drugs Market, By Route of Administration
      • 6.7.6.3 Spain Acute Migraine Drugs Market, By Availability
    • 6.7.7 Rest of Europe Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
      • 6.7.7.1 Rest of Europe Acute Migraine Drugs Market, By Drug Type
      • 6.7.7.2 Rest of Europe Acute Migraine Drugs Market, By Route of Administration
      • 6.7.7.3 Rest of Europe Acute Migraine Drugs Market, By Availability

7. Asia Pacific Acute Migraine Drugs Market: Historic and Forecast (2018-2028)

  • 7.1 Asia Pacific Acute Migraine Drugs Market: Snapshot
  • 7.2 Asia Pacific Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
  • 7.3 Asia Pacific Acute Migraine Drugs Market: Key Factors
  • 7.4 Asia Pacific Acute Migraine Drugs Market Segmentation: By Drug Type
    • 7.4.1 Asia Pacific Acute Migraine Drugs Market, By Drug Type Overview
    • 7.4.2 Asia Pacific Acute Migraine Drugs Market Size, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)
    • 7.4.3 Asia Pacific Acute Migraine Drugs Market Size, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)
    • 7.4.4 Asia Pacific Acute Migraine Drugs Market Size, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)
    • 7.4.5 Asia Pacific Acute Migraine Drugs Market Size, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)
  • 7.5 Asia Pacific Acute Migraine Drugs Market Segmentation: By Route of Administration
    • 7.5.1 Asia Pacific Acute Migraine Drugs Market, By Route of Administration Overview
    • 7.5.2 Asia Pacific Acute Migraine Drugs Market Size, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)
    • 7.5.3 Asia Pacific Acute Migraine Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
    • 7.5.4 Asia Pacific Acute Migraine Drugs Market Size, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)
    • 7.5.5 Asia Pacific Acute Migraine Drugs Market Size, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)
  • 7.6 Asia Pacific Acute Migraine Drugs Market Segmentation: By Availability
    • 7.6.1 Asia Pacific Acute Migraine Drugs Market, By Availability Overview
    • 7.6.2 Asia Pacific Acute Migraine Drugs Market Size, By Over the Counter, By Value, 2018H-2028F (USD Billion & CAGR)
    • 7.6.3 Asia Pacific Acute Migraine Drugs Market Size, By Prescription, By Value, 2018H-2028F (USD Billion & CAGR)
  • 7.7 Asia Pacific Acute Migraine Drugs Market Segmentation: By Country
    • 7.7.1 Asia Pacific Acute Migraine Drugs Market, By Country Overview
    • 7.7.2 China Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
      • 7.7.2.1 China Acute Migraine Drugs Market, By Drug Type
      • 7.7.2.2 China Acute Migraine Drugs Market, By Route of Administration
      • 7.7.2.3 China Acute Migraine Drugs Market, By Availability
    • 7.7.3 Japan Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
      • 7.7.3.1 Japan Acute Migraine Drugs Market, By Drug Type
      • 7.7.3.2 Japan Acute Migraine Drugs Market, By Route of Administration
      • 7.7.3.3 Japan Acute Migraine Drugs Market, By Availability
    • 7.7.4 India Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
      • 7.7.4.1 India Acute Migraine Drugs Market, By Drug Type
      • 7.7.4.2 India Acute Migraine Drugs Market, By Route of Administration
      • 7.7.4.3 India Acute Migraine Drugs Market, By Availability
    • 7.7.5 Rest Of Asia Pacific Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
      • 7.7.5.1 Rest Of Asia Pacific Acute Migraine Drugs Market, By Drug Type
      • 7.7.5.2 Rest Of Asia Pacific Acute Migraine Drugs Market, By Route of Administration
      • 7.7.5.3 Rest Of Asia Pacific Acute Migraine Drugs Market, By Availability

8. Middle East & Africa Acute Migraine Drugs Market: Historic and Forecast (2018-2028)

  • 8.1 Middle East & Africa Acute Migraine Drugs Market: Snapshot
  • 8.2 Middle East & Africa Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)
  • 8.3 Middle East & Africa Acute Migraine Drugs Market: Key Factors
  • 8.4 Middle East & Africa Acute Migraine Drugs Market Segmentation: By Drug Type
    • 8.4.1 Middle East & Africa Acute Migraine Drugs Market, By Drug Type Overview
    • 8.4.2 Middle East & Africa Acute Migraine Drugs Market Size, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)
    • 8.4.3 Middle East & Africa Acute Migraine Drugs Market Size, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)
    • 8.4.4 Middle East & Africa Acute Migraine Drugs Market Size, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)
    • 8.4.5 Middle East & Africa Acute Migraine Drugs Market Size, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)
  • 8.5 Middle East & Africa Acute Migraine Drugs Market Segmentation: By Route of Administration
    • 8.5.1 Middle East & Africa Acute Migraine Drugs Market, By Route of Administration Overview
    • 8.5.1 Middle East & Africa Acute Migraine Drugs Market Size, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)
    • 8.5.1 Middle East & Africa Acute Migraine Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
    • 8.5.1 Middle East & Africa Acute Migraine Drugs Market Size, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)
    • 8.5.1 Middle East & Africa Acute Migraine Drugs Market Size, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)
  • 8.6 Middle East & Africa Acute Migraine Drugs Market Segmentation: By Availability
    • 8.6.1 Middle East & Africa Acute Migraine Drugs Market, By Availability Overview
    • 8.6.2 Middle East & Africa Acute Migraine Drugs Market Size, By Over the Counter, By Value, 2018H-2028F (USD Billion & CAGR)
    • 8.6.3 Middle East & Africa Acute Migraine Drugs Market Size, By Prescription, By Value, 2018H-2028F (USD Billion & CAGR)

9. Market Dynamics

  • 9.1 Impact assessment of Market Dynamics on Global Acute Migraine Drugs Market
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Trends

10. Industry Ecosystem Analysis

  • 10.1 Macro-Economic Factor Assessment
  • 10.2 Value Chain Analysis
  • 10.3 Porter's Five Forces Model

11. Competitive Positioning

  • 11.1 Companies' Product Positioning
  • 11.2 Market Position Matrix
  • 11.3 Market Share Analysis of Acute Migraine Drugs Market
  • 11.4 Company Profiles
    • 11.4.1 Eli Lilly and Company
    • 11.4.2 GSK plc.
    • 11.4.3 Bayer AG
    • 11.4.4 Johnson & Johnson
    • 11.4.5 Teva Pharmaceutical Industries Ltd.
    • 11.4.6 AbbVie Inc.
    • 11.4.7 Novartis
    • 11.4.8 Merck & Co., Inc.
    • 11.4.9 Pfizer Inc.
    • 11.4.10 Boehringer Ingelheim

12. About Us & Disclaimer

List of Figures

List of Figures

  • Figure 1: Migraine - Nurtec ODT and Ubrelvy patient's Therapy abandonment data
  • Figure 2: Migraine - Annual Sales of Triptans and Non-Triptans in the U.S
  • Figure 3: Global Acute Migraine Drugs Market Size, By Value, 2018-2021 (USD Billion)
  • Figure 4: Global Acute Migraine Drugs Market Size, By Value, 2022-2028 (USD Billion)
  • Figure 5: Global Acute Migraine Drugs Market Share, By Drug Type, 2021 (%)
  • Figure 6: Global Acute Migraine Drugs Market Size, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 7: Global Acute Migraine Drugs Market Absolute Opportunity, By Ergot Alkaloids, 2018-2028 (USD Billion)
  • Figure 8: Global Acute Migraine Drugs Market Size, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 9: Global Acute Migraine Drugs Market Absolute Opportunity, By Analgesics, 2018-2028 (USD Billion)
  • Figure 10: Global Acute Migraine Drugs Market Size, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 11: Global Acute Migraine Drugs Market Absolute Opportunity, By Triptans, 2018-2028 (USD Billion)
  • Figure 12: Global Acute Migraine Drugs Market Size, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 13: Global Acute Migraine Drugs Market Absolute Opportunity, By Other Drug Types, 2018-2028 (USD Billion)
  • Figure 14: Global Acute Migraine Drugs Market Size, By Intravenous, By Value, 2018H--2028F (USD Billion & CAGR)
  • Figure 15: Global Acute Migraine Drugs Market Absolute Opportunity, By Intravenous, 2018-2028 (USD Billion)
  • Figure 16: Global Acute Migraine Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 17: Global Acute Migraine Drugs Market Absolute Opportunity, By Oral, 2018-2028 (USD Billion)
  • Figure 18: Global Acute Migraine Drugs Market Size, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 19: Global Acute Migraine Drugs Market Absolute Opportunity, By Nasal, 2018-2028 (USD Billion)
  • Figure 20: Global Acute Migraine Drugs Market Size, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 21: Global Acute Migraine Drugs Market Absolute Opportunity, By Other Routes of Administration, 2018-2028 (USD Billion)
  • Figure 22: Global Acute Migraine Drugs Market Size, By Over The Counter, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 23: Global Acute Migraine Drugs Market Absolute Opportunity, By Over The Counter, 2018-2028 (USD Billion)
  • Figure 24: Global Acute Migraine Drugs Market Size, By Prescription, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 25: Global Acute Migraine Drugs Market Absolute Opportunity, By Prescription, 2018-2028 (USD Billion)
  • Figure 26: Americas Acute Migraine Drugs Market Size, By Value, 2018H-2028F (USD Billion)
  • Figure 27: Americas Acute Migraine Drugs Market Share, By Drug Type, 2021 (%)
  • Figure 28: Americas Acute Migraine Drugs Market, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 29: Americas Acute Migraine Drugs Market, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 30: Americas Acute Migraine Drugs Market, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 31: Americas Acute Migraine Drugs Market, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 32: Americas Acute Migraine Drugs Market, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 33: Americas Acute Migraine Drugs Market, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 34: Americas Acute Migraine Drugs Market, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 35: Americas Acute Migraine Drugs Market, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 36: Americas Acute Migraine Drugs Market, By Over The Counter Availability, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 37: Americas Acute Migraine Drugs Market, By Prescription Availability, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 38: United States Acute Migraine Drugs Market, By Value, 2018-2028 (USD Billion & CAGR)
  • Figure 39: United States Acute Migraine Drugs Market Value, By Drug Type, 2021 (USD Billion)
  • Figure 40: United States Acute Migraine Drugs Market Share, By Drug Type, By Value, 2021 (%)
  • Figure 41: United States Acute Migraine Drugs Market Share, By Route of Administration, By Value, 2021 (%)
  • Figure 42: United States Acute Migraine Drugs Market Share, By Availability, By Value, 2021 (%)
  • Figure 43: Canada Acute Migraine Drugs Market, By Value, 2018-2028 (USD Billion & CAGR)
  • Figure 44: Canada Acute Migraine Drugs Market Value, By Drug Type, 2021 (USD Billion)
  • Figure 45: Canada Acute Migraine Drugs Market Share, By Drug Type, By Value, 2021 (%)
  • Figure 46: Canada Acute Migraine Drugs Market Share, By Route of Administration, By Value, 2021 (%)
  • Figure 47: Canada Acute Migraine Drugs Market Share, By Availability, By Value, 2021 (%)
  • Figure 48: Rest of Americas Acute Migraine Drugs Market, By Value, 2018-2028 (USD Billion & CAGR)
  • Figure 49: Rest of Americas Acute Migraine Drugs Market Value, By Drug Type, 2021 (USD Billion)
  • Figure 50: Rest of Americas Acute Migraine Drugs Market Share, By Drug Type, By Value, 2021 (%)
  • Figure 51: Rest of Americas Acute Migraine Drugs Market Share, By Route of Administration, By Value, 2021 (%)
  • Figure 52: Rest of Americas Acute Migraine Drugs Market Share, By Availability, By Value, 2021 (%)
  • Figure 53: Europe Acute Migraine Drugs Market Size, By Value, 2018H-2028F (USD Billion)
  • Figure 54: Europe Acute Migraine Drugs Market Share, By Drug Type, 2021 (%)
  • Figure 55: Europe Acute Migraine Drugs Market, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 56: Europe Acute Migraine Drugs Market, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 57: Europe Acute Migraine Drugs Market, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 58: Europe Acute Migraine Drugs Market, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 59: Europe Acute Migraine Drugs Market, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 60: Europe Acute Migraine Drugs Market, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 61: Europe Acute Migraine Drugs Market, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 62: Europe Acute Migraine Drugs Market, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 63: Europe Acute Migraine Drugs Market, By Over The Counter Availability, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 64: Europe Acute Migraine Drugs Market, By Prescription Availability, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 65: Germany Acute Migraine Drugs Market, By Value, 2018-2028 (USD Billion & CAGR)
  • Figure 66: Germany Acute Migraine Drugs Market Value, By Drug Type, 2021 (USD Billion)
  • Figure 67: Germany Acute Migraine Drugs Market Share, By Drug Type, By Value, 2021 (%)
  • Figure 68: Germany Acute Migraine Drugs Market Share, By Route of Administration, By Value, 2021 (%)
  • Figure 69: Germany Acute Migraine Drugs Market Share, By Availability, By Value, 2021 (%)
  • Figure 70: United Kingdom Acute Migraine Drugs Market, By Value, 2018-2028 (USD Billion & CAGR)
  • Figure 71: United Kingdom Acute Migraine Drugs Market Value, By Drug Type, 2021 (USD Billion)
  • Figure 72: United Kingdom Acute Migraine Drugs Market Share, By Drug Type, By Value, 2021 (%)
  • Figure 73: United Kingdom Acute Migraine Drugs Market Share, By Route of Administration, By Value, 2021 (%)
  • Figure 74: United Kingdom Acute Migraine Drugs Market Share, By Availability, By Value, 2021 (%)
  • Figure 75: France Acute Migraine Drugs Market, By Value, 2018-2028 (USD Billion & CAGR)
  • Figure 76: France Acute Migraine Drugs Market Value, By Drug Type, 2021 (USD Billion)
  • Figure 77: France Acute Migraine Drugs Market Share, By Drug Type, By Value, 2021 (%)
  • Figure 78: France Acute Migraine Drugs Market Share, By Route of Administration, By Value, 2021 (%)
  • Figure 79: France Acute Migraine Drugs Market Share, By Availability, By Value, 2021 (%)
  • Figure 80: Italy Acute Migraine Drugs Market, By Value, 2018-2028 (USD Billion & CAGR)
  • Figure 81: Italy Acute Migraine Drugs Market Value, By Drug Type, 2021 (USD Billion)
  • Figure 82: Italy Acute Migraine Drugs Market Share, By Drug Type, By Value, 2021 (%)
  • Figure 83: Italy Acute Migraine Drugs Market Share, By Route of Administration, By Value, 2021 (%)
  • Figure 84: Italy Acute Migraine Drugs Market Share, By Availability, By Value, 2021 (%)
  • Figure 85: Spain Acute Migraine Drugs Market, By Value, 2018-2028 (USD Billion & CAGR)
  • Figure 86: Spain Acute Migraine Drugs Market Value, By Drug Type, 2021 (USD Billion)
  • Figure 87: Spain Acute Migraine Drugs Market Share, By Drug Type, By Value, 2021 (%)
  • Figure 88: Spain Acute Migraine Drugs Market Share, By Route of Administration, By Value, 2021 (%)
  • Figure 89: Spain Acute Migraine Drugs Market Share, By Availability, By Value, 2021 (%)
  • Figure 90: Rest of Europe Acute Migraine Drugs Market, By Value, 2018-2028 (USD Billion & CAGR)
  • Figure 91: Rest of Europe Acute Migraine Drugs Market Value, By Drug Type, 2021 (USD Billion)
  • Figure 92: Rest of Europe Acute Migraine Drugs Market Share, By Drug Type, By Value, 2021 (%)
  • Figure 93: Rest of Europe Acute Migraine Drugs Market Share, By Route of Administration, By Value, 2021 (%)
  • Figure 94: Rest of Europe Acute Migraine Drugs Market Share, By Availability, By Value, 2021 (%)
  • Figure 95: Asia Pacific Acute Migraine Drugs Market Size, By Value, 2018H-2028F (USD Billion)
  • Figure 96: Asia Pacific Acute Migraine Drugs Market Share, By Drug Type, 2021 (%)
  • Figure 97: Asia Pacific Acute Migraine Drugs Market, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 98: Asia Pacific Acute Migraine Drugs Market, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 99: Asia Pacific Acute Migraine Drugs Market, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 100: Asia Pacific Acute Migraine Drugs Market, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 101: Asia Pacific Acute Migraine Drugs Market, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 102: Asia Pacific Acute Migraine Drugs Market, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 103: Asia Pacific Acute Migraine Drugs Market, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 104: Asia Pacific Acute Migraine Drugs Market, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 105: Asia Pacific Acute Migraine Drugs Market, By Over The Counter Availability, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 106: Asia Pacific Acute Migraine Drugs Market, By Prescription Availability, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 107: China Acute Migraine Drugs Market, By Value, 2018-2028 (USD Billion & CAGR)
  • Figure 108: China Acute Migraine Drugs Market Value, By Drug Type, 2021 (USD Billion)
  • Figure 109: China Acute Migraine Drugs Market Share, By Drug Type, By Value, 2021 (%)
  • Figure 110: China Acute Migraine Drugs Market Share, By Route of Administration, By Value, 2021 (%)
  • Figure 111: China Acute Migraine Drugs Market Share, By Availability, By Value, 2021 (%)
  • Figure 112: Japan Acute Migraine Drugs Market, By Value, 2018-2028 (USD Billion & CAGR)
  • Figure 113: Japan Acute Migraine Drugs Market Value, By Drug Type, 2021 (USD Billion)
  • Figure 114: Japan Acute Migraine Drugs Market Share, By Drug Type, By Value, 2021 (%)
  • Figure 115: Japan Acute Migraine Drugs Market Share, By Route of Administration, By Value, 2021 (%)
  • Figure 116: Japan Acute Migraine Drugs Market Share, By Availability, By Value, 2021 (%)
  • Figure 117: India Acute Migraine Drugs Market, By Value, 2018-2028 (USD Billion & CAGR)
  • Figure 118: India Acute Migraine Drugs Market Value, By Drug Type, 2021 (USD Billion)
  • Figure 119: India Acute Migraine Drugs Market Share, By Drug Type, By Value, 2021 (%)
  • Figure 120: India Acute Migraine Drugs Market Share, By Route of Administration, By Value, 2021 (%)
  • Figure 121: India Acute Migraine Drugs Market Share, By Availability, By Value, 2021 (%)
  • Figure 122: Rest of Asia Pacific Acute Migraine Drugs Market, By Value, 2018-2028 (USD Billion & CAGR)
  • Figure 123: Rest of Asia Pacific Acute Migraine Drugs Market Value, By Drug Type, 2021 (USD Billion)
  • Figure 124: Rest of Asia Pacific Acute Migraine Drugs Market Share, By Drug Type, By Value, 2021 (%)
  • Figure 125: Rest of Asia Pacific Acute Migraine Drugs Market Share, By Route of Administration, By Value, 2021 (%)
  • Figure 126: Rest of Asia Pacific Acute Migraine Drugs Market Share, By Availability, By Value, 2021 (%)
  • Figure 127: Middle East & Africa Acute Migraine Drugs Market Size, By Value, 2018H-2028F (USD Billion)
  • Figure 128: Middle East & Africa Acute Migraine Drugs Market Share, By Drug Type, 2021 (%)
  • Figure 129: Middle East & Africa Acute Migraine Drugs Market, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 130: Middle East & Africa Acute Migraine Drugs Market, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 131: Middle East & Africa Acute Migraine Drugs Market, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 132: Middle East & Africa Acute Acute Migraine Drugs Market, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 133: Middle East & Africa Acute Acute Migraine Drugs Market, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 134: Middle East & Africa Acute Acute Migraine Drugs Market, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 135: Middle East & Africa Acute Acute Migraine Drugs Market, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 136: Middle East & Africa Acute Acute Migraine Drugs Market, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 137: Middle East & Africa Acute Acute Migraine Drugs Market, By Over The Counter Availability, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 138: Middle East & Africa Acute Acute Migraine Drugs Market, By Prescription Availability, By Value, 2018H-2028F (USD Billion & CAGR)
  • Figure 139: Global Impact of Drivers and Restraints
  • Figure 140: Market Share of Prominent Companies of Acute Migraine Drugs, 2021 (%)
  • Figure 141: Eli Lilly and Company Revenues, 2019-2021 (USD Million)
  • Figure 142: Eli Lilly and Company Revenues Revenue , By Business Segments, 2021 (%)
  • Figure 143: Eli Lilly and Company Revenues Revenue , By Business Segments, 2021 (%)
  • Figure 144: GSK plc. Revenues, 2019-2021 (USD Million)
  • Figure 145: GSK plc. Revenue , By Business Segments, 2021 (%)
  • Figure 146: GSK plc. Revenue , By Geographical Segments, 2021 (%)
  • Figure 147: Bayer AG . Revenues, 2019-2021 (USD Million)
  • Figure 148: Bayer AG . Revenue , By Business Segments, 2021 (%)
  • Figure 149: Bayer AG . Revenue , By Geographical; Segments, 2021 (%)
  • Figure 150: J&J Revenues, 2019-2021 (USD Million)
  • Figure 151: J&J Revenue , By Business Segments, 2021 (%)
  • Figure 152: JJ&J Revenue , By Geographical Segments, 2021 (%)
  • Figure 153: Teva Pharmaceuticals Revenues, 2019-2021 (USD Million)
  • Figure 154: Teva Pharmaceuticals Revenue , By Geographical Segments, 2021 (%)
  • Figure 155: AbbVie Inc. Revenues, 2019-2021 (USD Million)
  • Figure 156: AbbVie Inc. Revenue , Product Sales by Product Segment, 2021 (%)
  • Figure 157: AbbVie Inc. Revenue , By Geographical Segments, 2021 (%)
  • Figure 158: Novartis Revenues, 2019-2021 (USD million)
  • Figure 159: Novartis Revenue , By Business Segments, 2021 (%)
  • Figure 160: Novartis Revenue , By Geographical Segments, 2021 (%)
  • Figure 161: Merck & Co., Inc. Revenues, 2019-2021 (USD Million)
  • Figure 162: Merck & Co., Inc. Revenue , By Geographic segment, 2021 (%)
  • Figure 163: Merck & Co., Inc. Revenue , By Business Segments, 2021 (%)
  • Figure 164: Pfizer Inc. Revenues, 2019-2021 (USD Million)
  • Figure 165: Pfizer Inc. Revenue , By Business Segments- By Products, 2021 (%)
  • Figure 166: Pfizer Inc. Revenue , By Geographic Segments, 2021 (%)
  • Figure 167: Boehringer Ingelheim Revenues, 2019-2021 (USD Million)
  • Figure 168: Boehringer Ingelheim Revenue , By Business Segments- By Products, 2021 (%)
  • Figure 169: Boehringer Ingelheim Revenue , By Geographical Segments, 2021 (%)

List of Tables

Table A1: Global Impact of Macro Economic Factors, By Region

Table A2: Acute Migraine Drugs in Pipeline

Table A3: United States Acute Migraine Drugs Market, By Drug Type, By Value, 2018-2021 (USD Billion)

Table A4: United States Acute Migraine Drugs Market, By Drug Type, By Value, 2022-2028 (USD Billion)

Table A5: United States Acute Migraine Drugs Market, By Route of Administration, By Value, 2018-2021 (USD Billion)

Table A6: United States Acute Migraine Drugs Market, By Route of Administration, By Value, 2022-2028 (USD Billion)

Table A7: United States Acute Migraine Drugs Market, By Availability, By Value, 2018-2021 (USD Billion)

Table A8: United States Acute Migraine Drugs Market, By Availability, By Value, 2022-2028 (USD Billion)

Table A9: Canada Acute Migraine Drugs Market, By Drug Type, By Value, 2018-2021 (USD Billion)

Table A10: Canada Acute Migraine Drugs Market, By Drug Type, By Value, 2022-2028 (USD Billion)

Table A11: Canada Acute Migraine Drugs Market, By Route of Administration, By Value, 2018-2021 (USD Billion)

Table A12: Canada Acute Migraine Drugs Market, By Route of Administration, By Value, 2022-2028 (USD Billion)

Table A13: Canada Acute Migraine Drugs Market, By Availability, By Value, 2018-2021 (USD Billion)

Table A14: Canada Acute Migraine Drugs Market, By Availability, By Value, 2022-2028 (USD Billion)

Table A15: Rest of Americas Acute Migraine Drugs Market, By Drug Type, By Value, 2018-2021 (USD Billion)

Table A16: Rest of Americas Acute Migraine Drugs Market, By Drug Type, By Value, 2022-2028 (USD Billion)

Table A17: Rest of Americas Acute Migraine Drugs Market, By Route of Administration, By Value, 2018-2021 (USD Billion)

Table A18: Rest of Americas Acute Migraine Drugs Market, By Route of Administration, By Value, 2022-2028 (USD Billion)

Table A19: Rest of Americas Acute Migraine Drugs Market, By Availability, By Value, 2018-2021 (USD Billion)

Table A20: Rest of Americas Acute Migraine Drugs Market, By Availability, By Value, 2022-2028 (USD Billion)

Table A21: Germany Acute Migraine Drugs Market, By Drug Type, By Value, 2018-2021 (USD Billion)

Table A22: Germany Acute Migraine Drugs Market, By Drug Type, By Value, 2022-2028 (USD Billion)

Table A23: Germany Acute Migraine Drugs Market, By Route of Administration, By Value, 2018-2021 (USD Billion)

Table A24: Germany Acute Migraine Drugs Market, By Route of Administration, By Value, 2022-2028 (USD Billion)

Table A25: Germany Acute Migraine Drugs Market, By Availability, By Value, 2018-2021 (USD Billion)

Table A26: Germany Acute Migraine Drugs Market, By Availability, By Value, 2022-2028 (USD Billion)

Table A27: United Kingdom Acute Migraine Drugs Market, By Drug Type, By Value, 2018-2021 (USD Billion)

Table A28: United Kingdom Acute Migraine Drugs Market, By Drug Type, By Value, 2022-2028 (USD Billion)

Table A29: United Kingdom Acute Migraine Drugs Market, By Route of Administration, By Value, 2018-2021 (USD Billion)

Table A30: United Kingdom Acute Migraine Drugs Market, By Route of Administration, By Value, 2022-2028 (USD Billion)

Table A31: United Kingdom Acute Migraine Drugs Market, By Availability, By Value, 2018-2021 (USD Billion)

Table A32: United Kingdom Acute Migraine Drugs Market, By Availability, By Value, 2022-2028 (USD Billion)

Table A33: France Acute Migraine Drugs Market, By Drug Type, By Value, 2018-2021 (USD Billion)

Table A34: France Acute Migraine Drugs Market, By Drug Type, By Value, 2022-2028 (USD Billion)

Table A35: France Acute Migraine Drugs Market, By Route of Administration, By Value, 2018-2021 (USD Billion)

Table A36: France Acute Migraine Drugs Market, By Route of Administration, By Value, 2022-2028 (USD Billion)

Table A37: France Acute Migraine Drugs Market, By Availability, By Value, 2018-2021 (USD Billion)

Table A38: France Acute Migraine Drugs Market, By Availability, By Value, 2022-2028 (USD Billion)

Table A39: Italy Acute Migraine Drugs Market, By Drug Type, By Value, 2018-2021 (USD Billion)

Table A40: Italy Acute Migraine Drugs Market, By Drug Type, By Value, 2022-2028 (USD Billion)

Table A41: Italy Acute Migraine Drugs Market, By Route of Administration, By Value, 2018-2021 (USD Billion)

Table A42: Italy Acute Migraine Drugs Market, By Route of Administration, By Value, 2022-2028 (USD Billion)

Table A43: Italy Acute Migraine Drugs Market, By Availability, By Value, 2018-2021 (USD Billion)

Table A44: Italy Acute Migraine Drugs Market, By Availability, By Value, 2022-2028 (USD Billion)

Table A45: Spain Acute Migraine Drugs Market, By Drug Type, By Value, 2018-2021 (USD Billion)

Table A46: Spain Acute Migraine Drugs Market, By Drug Type, By Value, 2022-2028 (USD Billion)

Table A47: Spain Acute Migraine Drugs Market, By Route of Administration, By Value, 2018-2021 (USD Billion)

Table A48: Spain Acute Migraine Drugs Market, By Route of Administration, By Value, 2022-2028 (USD Billion)

Table A49: Spain Acute Migraine Drugs Market, By Availability, By Value, 2018-2021 (USD Billion)

Table A50: Spain Acute Migraine Drugs Market, By Availability, By Value, 2022-2028 (USD Billion)

Table A51: Rest of Europe Acute Migraine Drugs Market, By Drug Type, By Value, 2018-2021 (USD Billion)

Table A52: Rest of Europe Acute Migraine Drugs Market, By Drug Type, By Value, 2022-2028 (USD Billion)

Table A53: Rest of Europe Acute Migraine Drugs Market, By Route of Administration, By Value, 2018-2021 (USD Billion)

Table A54: Rest of Europe Acute Migraine Drugs Market, By Route of Administration, By Value, 2022-2028 (USD Billion)

Table A55: Rest of Europe Acute Migraine Drugs Market, By Availability, By Value, 2018-2021 (USD Billion)

Table A56: Rest of Europe Acute Migraine Drugs Market, By Availability, By Value, 2022-2028 (USD Billion)

Table A57: China Acute Migraine Drugs Market, By Drug Type, By Value, 2018-2021 (USD Billion)

Table A58: China Acute Migraine Drugs Market, By Drug Type, By Value, 2022-2028 (USD Billion)

Table A59: China Acute Migraine Drugs Market, By Route of Administration, By Value, 2018-2021 (USD Billion)

Table A60: China Acute Migraine Drugs Market, By Route of Administration, By Value, 2022-2028 (USD Billion)

Table A61: China Acute Migraine Drugs Market, By Availability, By Value, 2018-2021 (USD Billion)

Table A62: China Acute Migraine Drugs Market, By Availability, By Value, 2022-2028 (USD Billion)

Table A63: Japan Acute Migraine Drugs Market, By Drug Type, By Value, 2018-2021 (USD Billion)

Table A64: Japan Acute Migraine Drugs Market, By Drug Type, By Value, 2022-2028 (USD Billion)

Table A65: Japan Acute Migraine Drugs Market, By Route of Administration, By Value, 2018-2021 (USD Billion)

Table A66: Japan Acute Migraine Drugs Market, By Route of Administration, By Value, 2022-2028 (USD Billion)

Table A67: Japan Acute Migraine Drugs Market, By Availability, By Value, 2018-2021 (USD Billion)

Table A68: Japan Acute Migraine Drugs Market, By Availability, By Value, 2022-2028 (USD Billion)

Table A69: India Acute Migraine Drugs Market, By Drug Type, By Value, 2018-2021 (USD Billion)

Table A70: India Acute Migraine Drugs Market, By Drug Type, By Value, 2022-2028 (USD Billion)

Table A71: India Acute Migraine Drugs Market, By Route of Administration, By Value, 2018-2021 (USD Billion)

Table A72: India Acute Migraine Drugs Market, By Route of Administration, By Value, 2022-2028 (USD Billion)

Table A73: India Acute Migraine Drugs Market, By Availability, By Value, 2018-2021 (USD Billion)

Table A74: India Acute Migraine Drugs Market, By Availability, By Value, 2022-2028 (USD Billion)

Table A75: Rest of Asia Pacific Acute Migraine Drugs Market, By Drug Type, By Value, 2018-2021 (USD Billion)

Table A76: Rest of Asia Pacific Acute Migraine Drugs Market, By Drug Type, By Value, 2022-2028 (USD Billion)

Table A77: Rest of Asia Pacific Acute Migraine Drugs Market, By Route of Administration, By Value, 2018-2021 (USD Billion)

Table A78: Rest of Asia Pacific Acute Migraine Drugs Market, By Route of Administration, By Value, 2022-2028 (USD Billion)

Table A79: Rest of Asia Pacific Acute Migraine Drugs Market, By Availability, By Value, 2018-2021 (USD Billion)

Table A80: Rest of Asia Pacific Acute Migraine Drugs Market, By Availability, By Value, 2022-2028 (USD Billion)

Table A81: Eli Lilly and Company Financials, 2019-2021

Table A82: GSK plc. Financials, 2019-2021

Table A83: Bayer AG Financials, 2019-2021

Table A84: Johnson & Johnson Financials, 2019-2021

Table A85: Teva Pharmaceuticals Financials, 2019-2021

Table A86: AbbVie Inc. Financials, 2019-2021

Table A87: Novartis Financials, 2019-2021

Table A88: Merck & Co., Inc. Financials, 2019-2021

Table A89: Pfizer Inc. Financials, 2019-2021

Table A90: Boehringer Ingelheim Financials, 2019-2021